Comparison of Treatment Recommendations by Molecular Tumor Boards Worldwide.
暂无分享,去创建一个
Mario Lamping | Ulrich Keilholz | Damian T. Rieke | Klaus H. Metzeler | Serge Leyvraz | Mark E. Burkard | M. Burkard | K. Metzeler | D. Rieke | S. Leyvraz | U. Keilholz | Christophe Le Tourneau | N. Basté | Marissa Schuh | Neus Basté | M. Lamping | Marissa Schuh | C. le Tourneau
[1] Benjamin M. Good,et al. Organizing knowledge to enable personalization of medicine in cancer , 2014, Genome Biology.
[2] Amber M. Johnson,et al. A decision support framework for genomically informed investigational cancer therapy. , 2015, Journal of the National Cancer Institute.
[3] BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers , 2017, Nature Communications.
[4] Theresa Zhang,et al. Personalized genomic analyses for cancer mutation discovery and interpretation , 2015, Science Translational Medicine.
[5] E. Mardis,et al. Prioritizing targets for precision cancer medicine. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] Razelle Kurzrock,et al. Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis. , 2016, JAMA oncology.
[7] Matthew S. Lebo,et al. Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium. , 2016, American journal of human genetics.
[8] P. Jänne,et al. SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] V. Prasad,et al. Characteristics of Exceptional or Super Responders to Cancer Drugs. , 2015, Mayo Clinic proceedings.
[10] Subha Madhavan,et al. Somatic cancer variant curation and harmonization through consensus minimum variant level data , 2016, Genome Medicine.
[11] Steven J. M. Jones,et al. CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer , 2017, Nature Genetics.